I will provide a comprehensive financial analysis of Alnylam (ALNY)


Alnylam Pharmaceuticals Inc.
(ALNY) is a leading biopharmaceutical company in the healthcare sector. The company is mainly focused on the discovery and development of RNA interference (RNAi) therapeutics for the treatment of genetic, cardio-metabolic, and hepatic infectious diseases. ALNY has a market capitalization of approximately $23 billion as of March 2023, and its stock is traded on the NASDAQ Global Select Market.

Financial Performance:

ALNY’s financial performance has been volatile in recent years. Its revenue has been growing over the past five years and reached $1.04 billion in 2022, up from $846 million in 2021, indicating a growth of approximately 23%. However, the company has been experiencing significant net losses, with a net loss of $1.13 billion in 2022, compared to a net loss of $974 million in 2021.
This trend has been due to the company’s ongoing research and development costs as it continues to invest heavily in its RNAi platform.


ALNY has been experiencing negative profitability indicators for the last five years. The company’s net profit margin was negative 109.04% in 2022, down from negative 115.16% in 2021. Furthermore, its operating margin was negative 75.68% in 2022, indicating that the company has yet to achieve a sustainable level of profitability.

Valuation Measures:

ALNY’s valuation metrics suggest that the company is currently overvalued. Its forward price-to-earnings ratio (P/E) is -26.99, indicating that the market expects the company to continue generating losses in the near future. ALNY has a negative earnings per share (EPS) of $-9.29 in 2022, indicating that the company did not generate profits per share during this period.
Furthermore, the company has a negative return on equity (ROE) of -526.14%, indicating that the company’s shareholders did not generate profits from their investments in the company.

Investment Considerations:

ALNY’s stock may not be suitable for investors seeking stable and predictable returns due to its volatile financial performance. However, for investors with a high-risk tolerance, ALNY may offer significant potential for future returns.
The company’s pipeline of RNAi therapies has the potential to address unmet medical needs in several therapeutic areas, which may drive long-term growth for the company.
Additionally, ALNY’s strong partnerships with leading pharmaceutical companies such as Regeneron and Sanofi, may provide the company with additional resources and expertise to continue developing its pipeline.


ALNY is a leading biopharmaceutical company in the healthcare sector with a market capitalization of approximately $23 billion. However, the company’s volatile financial performance and negative profitability indicators make its stock a high-risk investment. Investors seeking stable and predictable returns may want to consider other investment options. Nevertheless, ALNY’s strong partnerships and innovative RNAi platform suggest significant potential for long-term growth, making it a high-risk, high-reward investment opportunity.
As with all investments, it is crucial to conduct extensive research, including analyzing financial statements and market trends, before making an investment decision.

[1] Yahoo Finance. (2023). Alnylam Pharmaceuticals Inc. (ALNY) Income Statement. https://finance.yahoo.com/
[2] Nasdaq. (2023). Alnylam Pharmaceuticals Inc. (ALNY) Stock Comparison. https://www.nasdaq.com/

Scroll to Top